NEW YORK--(BUSINESS WIRE)--Oct 3, 2025-- Broadwood Partners, L.P. and its affiliates (collectively, “Broadwood”), holders of approximately 27.5% of the outstanding common stock of STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA), today announced that it has published a presentation outlining why stockholders should vote on Broadwood’s GREEN Proxy Card “ AGAINST ” the proposed acquisition of the Company by an affiliate of Alcon Inc. (NYSE: ALC) on the terms announced on August 5, 2025. The 81-page presentation is available here and on www.LetSTAARShine.com. Neal Bradsher, President of Broadwood, stated: “We believe that there was no compelling reason to sell STAAR at this time.